Cargando…

Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective

Several biologic treatments are available in addition to intravenous also in subcutaneous form for treatment of chronic diseases. Benefits of the subcutaneous application of drugs include self-administration by the patient, shorter time of application process with less infusion related adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonaitis, Laimas, Marković, Srdjan, Farkas, Klaudia, Gheorghe, Liana, Krznarić, Željko, Salupere, Riina, Mokricka, Viktorija, Spassova, Zoya, Gatev, Dimo, Grosu, Isabella, Lijović, Anton, Mitrović, Olga, Saje, Mateja, Schafer, Eszter, Uršič, Viktor, Roblek, Tina, Drobne, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654488/
https://www.ncbi.nlm.nih.gov/pubmed/34879868
http://dx.doi.org/10.1186/s12919-021-00230-7
_version_ 1784611870494162944
author Jonaitis, Laimas
Marković, Srdjan
Farkas, Klaudia
Gheorghe, Liana
Krznarić, Željko
Salupere, Riina
Mokricka, Viktorija
Spassova, Zoya
Gatev, Dimo
Grosu, Isabella
Lijović, Anton
Mitrović, Olga
Saje, Mateja
Schafer, Eszter
Uršič, Viktor
Roblek, Tina
Drobne, David
author_facet Jonaitis, Laimas
Marković, Srdjan
Farkas, Klaudia
Gheorghe, Liana
Krznarić, Željko
Salupere, Riina
Mokricka, Viktorija
Spassova, Zoya
Gatev, Dimo
Grosu, Isabella
Lijović, Anton
Mitrović, Olga
Saje, Mateja
Schafer, Eszter
Uršič, Viktor
Roblek, Tina
Drobne, David
author_sort Jonaitis, Laimas
collection PubMed
description Several biologic treatments are available in addition to intravenous also in subcutaneous form for treatment of chronic diseases. Benefits of the subcutaneous application of drugs include self-administration by the patient, shorter time of application process with less infusion related adverse events and consequently lower healthcare costs. With appropriate education and support patients are able to administer their treatments at home. This leads to improvement of quality of life, reduction of time needed to travel to the healthcare institution and consequently also reduces costs also for the patient. Over one million residents in the USA and 2.5 million in Europe are estimated to have inflammatory bowel disease (IBD), with substantial costs for health care. These estimates do not factor in the ‘real’ price of IBD, which can impede career aspirations, instil social stigma and impair quality of life in patients. The Virtual Community Meeting, which offered an exchange of experience and opinions from healthcare professionals who are active in treating IBD, and patients with this chronic disease, revealed in-depth arguments and answers to some essential questions: which patients prefer subcutaneous over intravenous dosing; which patients continue to favour intravenous infusions; what are the limitations regarding both applications; what is the patient’s role in therapeutical decision-making and how does IBD affect the patient’s work, finances and quality of life? The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from the health-economic, scientific, and personal perspectives. The meeting offered strong confirmation that most of the patients and healthcare professionals prefer subcutaneous over intravenous drug administration but emphasise the management of risks associated with treatment compliance. Patient education provided by the IBD team in this regard is mandatory. Quality of life of patients is poorer during active disease, but the findings that it can improve over time, including as a result of home- or self-administration of biologics, may be encouraging for individuals with this chronic disease.
format Online
Article
Text
id pubmed-8654488
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86544882021-12-09 Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective Jonaitis, Laimas Marković, Srdjan Farkas, Klaudia Gheorghe, Liana Krznarić, Željko Salupere, Riina Mokricka, Viktorija Spassova, Zoya Gatev, Dimo Grosu, Isabella Lijović, Anton Mitrović, Olga Saje, Mateja Schafer, Eszter Uršič, Viktor Roblek, Tina Drobne, David BMC Proc Meeting Report Several biologic treatments are available in addition to intravenous also in subcutaneous form for treatment of chronic diseases. Benefits of the subcutaneous application of drugs include self-administration by the patient, shorter time of application process with less infusion related adverse events and consequently lower healthcare costs. With appropriate education and support patients are able to administer their treatments at home. This leads to improvement of quality of life, reduction of time needed to travel to the healthcare institution and consequently also reduces costs also for the patient. Over one million residents in the USA and 2.5 million in Europe are estimated to have inflammatory bowel disease (IBD), with substantial costs for health care. These estimates do not factor in the ‘real’ price of IBD, which can impede career aspirations, instil social stigma and impair quality of life in patients. The Virtual Community Meeting, which offered an exchange of experience and opinions from healthcare professionals who are active in treating IBD, and patients with this chronic disease, revealed in-depth arguments and answers to some essential questions: which patients prefer subcutaneous over intravenous dosing; which patients continue to favour intravenous infusions; what are the limitations regarding both applications; what is the patient’s role in therapeutical decision-making and how does IBD affect the patient’s work, finances and quality of life? The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from the health-economic, scientific, and personal perspectives. The meeting offered strong confirmation that most of the patients and healthcare professionals prefer subcutaneous over intravenous drug administration but emphasise the management of risks associated with treatment compliance. Patient education provided by the IBD team in this regard is mandatory. Quality of life of patients is poorer during active disease, but the findings that it can improve over time, including as a result of home- or self-administration of biologics, may be encouraging for individuals with this chronic disease. BioMed Central 2021-12-09 /pmc/articles/PMC8654488/ /pubmed/34879868 http://dx.doi.org/10.1186/s12919-021-00230-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Meeting Report
Jonaitis, Laimas
Marković, Srdjan
Farkas, Klaudia
Gheorghe, Liana
Krznarić, Željko
Salupere, Riina
Mokricka, Viktorija
Spassova, Zoya
Gatev, Dimo
Grosu, Isabella
Lijović, Anton
Mitrović, Olga
Saje, Mateja
Schafer, Eszter
Uršič, Viktor
Roblek, Tina
Drobne, David
Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
title Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
title_full Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
title_fullStr Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
title_full_unstemmed Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
title_short Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
title_sort intravenous versus subcutaneous delivery of biotherapeutics in ibd: an expert’s and patient’s perspective
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654488/
https://www.ncbi.nlm.nih.gov/pubmed/34879868
http://dx.doi.org/10.1186/s12919-021-00230-7
work_keys_str_mv AT jonaitislaimas intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT markovicsrdjan intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT farkasklaudia intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT gheorgheliana intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT krznariczeljko intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT salupereriina intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT mokrickaviktorija intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT spassovazoya intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT gatevdimo intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT grosuisabella intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT lijovicanton intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT mitrovicolga intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT sajemateja intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT schafereszter intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT ursicviktor intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT roblektina intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective
AT drobnedavid intravenousversussubcutaneousdeliveryofbiotherapeuticsinibdanexpertsandpatientsperspective